Axogen Second Quarter 2025 Earnings: Beats Expectations

Simply Wall St

August 06, 2025

NasdaqCM:AXGN 1 Year Share Price vs Fair Value

Explore Axogen's Fair Values from the Community and select yours

Axogen (NASDAQ:AXGN) Second Quarter 2025 Results

Key Financial Results

Revenue: US$56.7m (up 18% from 2Q 2024).
Net income: US$579.0k (up from US$1.92m loss in 2Q 2024).
Profit margin: 1.0% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue.
EPS: US$0.013 (up from US$0.044 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-history — NasdaqCM:AXGN Earnings and Revenue History August 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Axogen Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 7.7%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 2.2% from a week ago.

Risk Analysis

Be aware that Axogen is showing 1 warning sign in our investment analysis that you should know about...

Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.